Efficacy evaluation | AS-SMP 3 days (N = 435) | AS-SMP 24 hours (N = 418) | AL 3 days (N = 392) |
---|---|---|---|
ETF – n (%) | 0 | 0 | 1(0.3%) |
LCF – n (%, 95%CI) | 3 (0.7%,0.1–2.0) | 2 (0.5%,0.1–1.7) | 0 |
LPF – n (%) | 0 | 0 | 0 |
ACPR – n (%, 95%CI) | 432 (99.3%,98.0–99.9) | 416 (99.5%,98.3–99.9) | 391 (99.7%,98.6–100.0) |
Reinfection rate – (%, 95%CI) | 12 (2.8%,1.4–4.8) | 13 (3.1%,1.7–5.3) | 14 (3.6%,2.0–5.9) |